云顶新耀首次实现年度商业化盈利,称医保产品落地符合预期

澎湃新闻
26 Mar

IgA肾病治疗药物增长1581%,氟环素类抗菌药物增长256%,港股创新药企云顶新耀2024年首度实现了年度商业化层面的盈利,但受无形资产减值亏损影响,亏损净额有所扩大。3月26日,云顶新耀(1952.HK)发布2024年度业绩报告。报告显示,公司全年收入达7.07亿元,同比增长461%;亏损净额为10.41亿元,同比2023年的8.45亿元有所扩大。云顶新耀称,主要由于2024年上半年与mRNA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10